Taysha Gene Therapies TSHA
Valuation
Multiples measured against the stock's own five-year history
Below its usual level · 22nd percentile, 5-year average -4.8x
Around its usual level · 42nd percentile, 5-year average 4.6x
#4063 of 5330 stocks by PB (1 = cheapest)
Near the top of its 5-year range · 92nd percentile, 5-year average 71.6x
#5022 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 3.74 | – | 4.56 | 42% (cheaper than usual) | #4063 of 5330 (1 = cheapest) |
| PE | -9.76 | -7.32 | -4.84 | 22% (cheaper than usual) | – |
| PS | 243.72 | 524.97 | 71.60 | 92% (pricier than usual) | #5022 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on TSHA.
Sign in to join the discussion.